Chemistry Reference
In-Depth Information
[111] Olejniczak, E. T., Hajduk, P. J., Marcotte, P. A., Nettesheim, D. G., Meadows, R. P., Edalji, R.,
Holzman, T. F., and Fesik, S. W. (1997). Stromelysin Inhibitors designed from weakly bound
fragments: effects of linking and cooperativity.
Journal of the American Chemical Society
119
, 5828-5832.
[112] Huth, J. R., Park, C., Petros, A. M., Kunzer, A. R., Wendt, M. D., Wang, X. L., Lynch, C. L.,
Mack, J. C., Swift, K. M., Judge, R. A., Chen, J., Richardson, P. L., Jin, S., Tahir, S. K., Matay-
oshi, E. D., Dorwin, S. A., Ladror, U. S., Severin, J. M., Walter, K. A., Bartley, D. M., Fesik, S.
W., Elmore, S. W., and Hajduk, P. J. (2007). Discovery and design of novel HSP90 inhibitors
using multiple fragment-based design strategies.
Chemical Biology and Drug Design
70
, 1-12.
[113] Jencks, W. P. (1981). On the attribution and additivity of binding energies.
Proceedings of the
National Academy of Sciences of the United States of America
78
, 4046-4050.
[114] Farmer, P. S., and Ariens, E. J. (1982). Speculations on the design of nonpeptidic
peptidomimetics.
Trends in Pharmacological Science
3
, 362-365.
[115] Zartler, E. R., Hanson, J., Jones, B. E., Kline, A. D., Martin, G., Mo, H., Shapiro, M. J., Wang,
R., Wu, H., and Yan, J. (2003). RAMPED-UP NMR: multiplexed NMR-based screening for
drug discovery.
Journal of the American Chemical Society
125
, 10941-10946.
[116] Cummings, M. D., Farnum, M. A., and Nelen, M. I. (2006). Universal screening methods and
applications of ThermoFluor (R).
Journal of Biomolecular Screening
11
, 854-863.
[117] Houston, J. G., Banks, M. N., Binnie, M., Brenner, S., O'Connell, J., and Petrillo, E. W.
(2008). Case study: impact of technology investment on lead discovery at Bristol-Myers
Squibb, 1998-2006.
Drug Discovery Today
13
, 44-51.
[118] Niesen, F. H., Berglund, H., andVedadi, M. (2007). The use of differential scanning fluorimetry
to detect ligand interactions that promote protein stability.
Nature Protocols
2
, 2212-2221.